Evidence map›Paper›PMID 42092956›Full record

ArticleCardiovascular diabetology2026

CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.

Oliver Schnell, Arnav Agarwal, Michel Azizi, Dennis Ballwieser, Katharine Barnard-Kelly, Tadej Battelino, Dennis Ballwieser, Matthias Blüher, Elisabetta Bugianesi, Ana Cebrian and 42 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

52 authors.

Oliver SchnellForschergruppe Diabetes E. V., Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg, Germany. oliver.schnell@lrz.uni-muenchen.de.
Arnav AgarwalDivision of General Internal Medicine, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Michel AziziUniversité Paris Cité, INSERM Centre d'Investigation Clinique 1418, Paris, France.
Dennis BallwieserWort & Bild Verlag, Baierbrunn, Germany.
Katharine Barnard-KellySouthern Health NHS Foundation Trust, Southampton, UK.
Tadej BattelinoUniversity Medical Center, Ljubljana, Slovenia.
Dennis BallwieserWort & Bild Verlag, Baierbrunn, Germany.
Matthias BlüherHelmholtz Institute for Metabolic, Obesity, and Vascular Research (HI-MAG), Leipzig, Germany.
Elisabetta BugianesiDepartment of Medical Sciences, University of Turin, Turin, Italy.
Ana CebrianCartagena Casco Health Center, 30201, Murcia, Spain.
Antonio CerielloIRCCS MultiMedica, Milan, Italy.
Pratik ChoudharyDiabetes Research Centre, College of Life Sciences, University of Leicester, Leicester, UK.
Thomas DanneNOVA Medical School, Lisbon, Portugal.
Colin M DayanCardiff University School of Medicine, Cardiff, UK.
Stefano Del PratoInterdisciplinary Research Center "Health Science", Sant'Anna School of Advanced Studies, Pisa, Italy.
Robert H EckelUniversity of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Paola FiorettoFaculty of Medicine, University of Padova, Padua, Italy.
Timothy GarveyDepartment of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, USA.
Jennifer B GreenDuke Clinical Research Institute, Duke University, Durham, NC, USA.
Hiddo J L HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Rury R HolmanDiabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Baruch ItzhakClalit Health Services, Haifa, Israel.
Stephan JacobDepartment of Internal Medicine, Endocrinology, and Diabetology, Cardiometabolic Institute, Villingen-Schwenningen, Germany.
Pardeep S JhundCardiovascular Research Centre, School of Cardiovascular and Metabolic Health, British Heart Foundation, University of Glasgow, Glasgow, UK.
Linong JiPeking University People's Hospital, Xicheng District, Beijing, China.
Parminder K JudgeRenal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Kamlesh KhuntiDiabetes Research Centre, College of Life Sciences, University of Leicester, Leicester, UK.
Marko KorenjakEuropean Liver Patients' Association, Brussels, Belgium.
Andrew J KrentzSchool of Life Course & Population Health Sciences, King's College London, London, WC2R 2LS, UK.
Ekaterini LambrinouDepartment of Nursing, Cyprus University of Technology, Limassol, Cyprus.
Peter LibbyHeart and Vascular Institute, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Julia K MaderDivision of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
Johannes F E MannKuratorium Für Heimdialyse Kidney Center, Munich, Germany.
Nikolaus MarxClinic for Cardiology, Angiology and Internal Intensive Care Medicine (Medical Clinic I), RWTH Aachen University Hospital, Aachen, Germany.
Chantal MathieuDepartment of Endocrinology, Catholic University of Leuven, Louvain, Belgium.
John J V McMurraySchool of Cardiovascular and Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Dirk Müller-WielandClinic for Cardiology, Angiology and Internal Intensive Care Medicine (Medical Clinic I), RWTH Aachen University Hospital, Aachen, Germany.
Nikolaos PapanasDiabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
Dipesh C PatelDivision of Medicine, Department of Diabetes, University College London, Royal Free Campus, London, UK.
Andreas F H PfeifferDepartment of Endocrinology and Metabolic Diseases, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
Susanne Reger-TanDepartment of Diabetes and Endocrinology, Heart and Diabetes Center NRW, Faculty of Medicine, University Hospital, Ruhr-University Bochum, OWL University of Bielefeld, Bad Oeynhausen, Germany.
Helena W RodbardEndocrine and Metabolic Consultants, Rockville, MD, USA.
Giuseppe M C RosanoDepartment of Human Sciences and Promotion of Quality of Life, San Raffaele Open University of Rome, Rome, Italy.
Banshi SabooDiacare-Diabetes Care and Hormone Clinic, Ahmedabad, India.
Naoki SatoDepartment of Cardiovascular Medicine, Kawaguchi Cardiovascular and Respiratory Hospital, Kawaguchi, Japan.
Scott D SolomonCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Eberhard StandlForschergruppe Diabetes E. V., Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg, Germany.
Frank TackeDepartment of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
Pinar TopseverDepartment of Family Medicine, Acıbadem Mehmet Ali Aydınlar University School of Medicine, Istanbul, Turkey.
Christoph WannerUniversity Clinic of Würzburg, Würzburg, Germany.
Sean WhartonWharton Weight Management Clinic, Toronto, Canada.
Veronika YoungSciarc GmbH, Baierbrunn, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 11th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 20-21, 2025. The Summit provided a multidisciplinary forum to review and discuss recent outcome trials investigating emerging pharmacological therapies targeting diseases of the cardiovascular-kidney-metabolic (CKM) continuum. This report highlights the unique developments of 2025 discussed during the Summit, including the first head-to-head CVOT (SURPASS-CVOT), the growing evidence base for combination therapies across the disease spectrum, new insights into the inflammatory component of the CKM syndrome, and relevant policy developments. The first part of this report summarizes pioneering clinical trials addressing combination therapy with finerenone and empagliflozin (CONFIDENCE), the oral glucagon-like peptide-1 (GLP-1) receptor agonists orforglipron (ATTAIN-1), and the aldosterone synthase inhibitor (ASI) baxdrostat (BaxHTN). The second part presents recent guideline and policy developments discussed by experts in endocrinology, diabetology, cardiology, nephrology, hepatology, and general practice. In addition, advances in medical technology, particularly in continuous glucose and ketone monitoring, are highlighted, as well as emerging therapies for diseases of the CKM continuum. These include pharmacological agents for a broad spectrum of metabolic disorders such as metabolic liver disease and type 1 Diabetes (T1D) alongside emphasis on the importance of early detection and innovative treatment strategies. The 12th Cardiovascular Outcome Trial Summit will be held virtually on 19-20 November 2026 ( http://www.cvot.org ).

Indexed as

Cardiovascular AgentsCardiovascular DiseasesKidney DiseasesAnimalsDrug Therapy, CombinationHumansHypoglycemic AgentsMineralocorticoid Receptor AntagonistsSodium-Glucose Transporter 2 InhibitorsTreatment OutcomeCardiovascular AgentsHypoglycemic AgentsMineralocorticoid Receptor AntagonistsSodium-Glucose Transporter 2 InhibitorsAldosterone synthase inhibitorsCGMDiabetesHeart failureIncretin mimeticsMASLDNonsteroidal mineralcorticoid receptor antagonistsObesitySGLT2 inhibitorSoluble guanylate cyclase stimulators

Identifiers

PMID42092956
PMCPMC13147710

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.